Zinzino isn’t for the faint-hearted. We are a Swedish, Nasdaq-listed powerhouse in evidence-based health with our corporate heart in Gothenburg and Oslo. We’ve done what most thought impossible: as one of the very few in our industry, we’ve successfully cracked the Chinese market - a unique feat that puts us in a global league of our own.

In 2025, we turned over 2 billion SEK with 1 million recurring customers .

Our target? 97% of the global population . The trajectory is clinical:

• 2035: 50 million customers
• 2050: 100 million+ customers

We don’t just sell ...